1126 related articles for article (PubMed ID: 19323590)
1. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
[TBL] [Abstract][Full Text] [Related]
4. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Brogan A; Mauskopf J; Talbird SE; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
[TBL] [Abstract][Full Text] [Related]
5. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
Pozniak A; Opravil M; Beatty G; Hill A; de Béthune MP; Lefebvre E
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1275-80. PubMed ID: 18844462
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.
Brogan AJ; Smets E; Mauskopf JA; Manuel SA; Adriaenssen I
Pharmacoeconomics; 2014 Sep; 32(9):903-17. PubMed ID: 24906477
[TBL] [Abstract][Full Text] [Related]
7. Resistance profile of darunavir: combined 24-week results from the POWER trials.
de Meyer S; Vangeneugden T; van Baelen B; de Paepe E; van Marck H; Picchio G; Lefebvre E; de Béthune MP
AIDS Res Hum Retroviruses; 2008 Mar; 24(3):379-88. PubMed ID: 18327986
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
Mauskopf J; Brogan A; Martin S; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
[TBL] [Abstract][Full Text] [Related]
10. Darunavir: a review of its use in the management of HIV-1 infection.
Deeks ED
Drugs; 2014 Jan; 74(1):99-125. PubMed ID: 24338166
[TBL] [Abstract][Full Text] [Related]
11. Darunavir: an effective protease inhibitor for HIV-infected patients.
Phung BC; Yeni P
Expert Rev Anti Infect Ther; 2011 Jun; 9(6):631-43. PubMed ID: 21692667
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
[TBL] [Abstract][Full Text] [Related]
13. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].
Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F
Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386
[TBL] [Abstract][Full Text] [Related]
14. A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.
Mauskopf J; Annemans L; Hill AM; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():1-16. PubMed ID: 21182340
[TBL] [Abstract][Full Text] [Related]
15. Darunavir: in the treatment of HIV-1 infection.
Fenton C; Perry CM
Drugs; 2007; 67(18):2791-801. PubMed ID: 18062724
[TBL] [Abstract][Full Text] [Related]
16. [Resistance to darunavir].
García Deltoro M
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():51-60. PubMed ID: 19195460
[TBL] [Abstract][Full Text] [Related]
17. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
Plosker GL; Scott LJ
Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
[TBL] [Abstract][Full Text] [Related]
18. Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.
McKeage K; Scott LJ
Paediatr Drugs; 2010 Apr; 12(2):123-31. PubMed ID: 20218748
[TBL] [Abstract][Full Text] [Related]
19. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
